Connor Iapoce

This February 2025 month in review covers key updates in endocrinology, including the end to the semaglutide shortage and new automated insulin delivery data.

The agency approved the first generic of the anticoagulant rivaroxaban to lower the risk of cardiovascular and thromboembolic events in adults with CAD and PAD.

The February 2025 month in review covers 7 key pipeline updates in ophthalmology, including regulatory approvals, label expansions, and topline trial results.

Marking the first stroke medicine approved in nearly 30 years, the single five-second intravenous bolus provides faster administration than the standard of care.

Castells discusses improvements in symptoms and quality of life scores for patients with indolent systemic mastocytosis across >2 years of the PIONEER trial.

The February 2025 cardiology review covers pipeline updates in lipid management, key regulatory acceptances and approvals, and shifting ASCVD trial endpoints.

The regulatory agency has assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 30, 2025.

Castells describes what’s missing from the current treatment landscape and the potential implications of elenestinib for indolent systemic mastocytosis.

Finerenone reduces outpatient worsening HF in patients with mildly reduced or preserved ejection fraction in a secondary analysis of FINEARTS-HF.

The regulatory agency has set a PDUFA target action date of August 27, 2025, for the investigational gene therapy.

Eyelid pressure patching concomitantly with a decellularized, dehydrated amniotic membrane could prove a novel method to address PCED.

Epioxa has been assigned a target action date of October 20, 2025, for the regulatory agency’s review of the NDA.

With this FDA approval, chenodiol tablets become the first approved drug to treat CTX, a rare lipid storage disease.

The US supply of semaglutide and semaglutide 2.4 mg now meets or exceeds current and projected demand, ending the long-running shortages of these blockbuster drugs.

Iron deficiency was more common in acute versus chronic heart failure, with notable differences in detection by numerous recommended definitions.

Clark describes visual and anatomic improvements with aflibercept 8 mg in the PULSAR extension study, with most patients achieving extended dosing regimens.

The first of two Phase 3 pivotal trials investigating sozinibercept, COAST completed its final week 52 visit in patients with wet AMD.

Dual SGLT1/2 inhibition with sotagliflozin significantly reduced both heart attacks and stroke in a prespecified secondary analysis of the SCORED trial.

Awarded to Luxa Biotechnology, early clinical from the first cohort of patients with dry AMD will be presented at an upcoming medical meeting.

Large ASCVD randomized controlled trials in prominent journals often use heterogeneous endpoints, which could influence reported results.

Our top 5 headlines include a target date for a cholesterol-lowering drug, long-term dermatology data, and an expanded dosing label for geographic atrophy.

Cardiovascular clinical outcome trials require a large number of sites to meet enrollment targets, but patient-per-site ratios were often low.

Mehrdad Ghoreishi, MD explores the latest advances in aortic disease treatment and the role of minimally invasive techniques.

The FDA approved an expanded label for avacincaptad pegol, removing limitations on the duration of dosing beyond 12 months.

Meta-analysis suggests iron therapy lowers the risk of heart failure hospitalization and cardiovascular death in patients with chronic kidney disease.

Olpasiran sustained reductions in oxidized phospholipids on apoB in patients with ASCVD and elevated Lp(a) levels in the Phase 2 dose-ranging trial.

Iron administration was linked to a decrease in platelet counts, even in the absence of preexisting thrombocytosis.

CELZ-201 reduced insulin dependency and stabilized HbA1c in 1-year follow-up data from the AlloStem pilot study in T2D.

Cardiovascular hospitalization rates were higher in the US than in Denmark, driven by a significant increase in heart failure and myocardial infarction hospitalizations.